Inhibrx Past Earnings Performance
Past criteria checks 0/6
Inhibrx's earnings have been declining at an average annual rate of -35.8%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 32.9% per year.
Key information
-35.8%
Earnings growth rate
-14.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -32.9% |
| Return on equity | -554.8% |
| Net Margin | -13,408.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23
Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results
May 16What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?
Jan 14Inhibrx's INBRX-109 wins FDA's Fast Track status
Jan 13Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors
Jan 05Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues
Nov 22Inhibrx EPS misses by $0.07
Nov 13Revenue & Expenses BreakdownBeta
How Inhibrx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -241 | 29 | 0 |
| 30 Sep 23 | 0 | -189 | 27 | 0 |
| 30 Jun 23 | 1 | -172 | 24 | 0 |
| 31 Mar 23 | 1 | -163 | 22 | 0 |
| 31 Dec 22 | 2 | -145 | 21 | 0 |
| 30 Sep 22 | 5 | -125 | 19 | 0 |
| 30 Jun 22 | 7 | -111 | 17 | 0 |
| 31 Mar 22 | 7 | -94 | 14 | 0 |
| 31 Dec 21 | 7 | -82 | 12 | 0 |
| 30 Sep 21 | 7 | -78 | 11 | 0 |
| 30 Jun 21 | 11 | -78 | 10 | 0 |
| 31 Mar 21 | 13 | -75 | 8 | 0 |
| 31 Dec 20 | 13 | -76 | 7 | 0 |
| 30 Sep 20 | 10 | -75 | 6 | 0 |
| 30 Jun 20 | 6 | -74 | 6 | 0 |
| 31 Mar 20 | 6 | -68 | 6 | 0 |
| 31 Dec 19 | 13 | -51 | 6 | 0 |
| 30 Sep 19 | 15 | -40 | 6 | 0 |
| 30 Jun 19 | 15 | -30 | 6 | 0 |
| 31 Mar 19 | 14 | -26 | 5 | 0 |
| 31 Dec 18 | 9 | -31 | 5 | 0 |
| 30 Sep 18 | 7 | -35 | 4 | 0 |
| 31 Dec 17 | 8 | -19 | 3 | 0 |
| 31 Dec 16 | 7 | -8 | 2 | 0 |
Quality Earnings: INBX is currently unprofitable.
Growing Profit Margin: INBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INBX is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare INBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: INBX has a negative Return on Equity (-554.81%), as it is currently unprofitable.